Eli Lilly and Company announced a $3.5 billion investment in the construction of a new pharmaceutical plant in the Lehigh Valley, Pennsylvania, which will become the company's first manufacturing facility in that state[1][2]. The new Fogelsville plant will manufacture injectable drugs and devices, including the experimental weight loss drug retatrutide, which is still in the trial phase[4]. The project will create at least 850 permanent jobs for engineers, scientists, operations personnel and laboratory technicians, with an additional 2,000 construction jobs created during construction[3][4]. Construction is expected to begin in 2026 and be completed in 2031[4]. Pennsylvania will contribute more than $100 million to the project through tax credits, grants and financial support for education[2][3]. The Lehigh Valley was selected from over 300 candidates due to its proximity to STEM-focused universities, a technical manufacturing economy and existing infrastructure[5]. This investment represents the largest life sciences project in Pennsylvania history and symbolizes the region's transformation from a former steel industry hub to a pharmaceutical research and manufacturing hub[1].